Literature DB >> 18997042

Mitogen-activated protein kinase signaling enhances sodium iodide symporter function and efficacy of radioiodide therapy in nonthyroidal cancer cells.

Kyung-Ho Jung1, Jin-Young Paik, Bong-Ho Ko, Kyung-Han Lee.   

Abstract

UNLABELLED: Although the success of sodium/iodide symporter (NIS) gene-based cancer therapy is critically dependent on the level of radioiodide accumulation attained, recent evidence indicates that successful therapy relies not solely on NIS amount but also crucially on its functional activity. In this study, we investigated the role of kinase-linked signaling on the regulation of NIS function in cancer cells.
METHODS: T47D human breast cancer and PC-12 rat pheochromocytoma cells were transduced with the human NIS genes via an adenoviral vector. Cells were measured for (125)I uptake, and the effects of activation or inhibition of protein kinase C (PKC) and mitogen-activated protein (MAP) kinase pathways were evaluated. Membrane localization of NIS was evaluated by biotinylation-immunoblotting and confocal microscopy. (131)I-mediated cancer cell killing was evaluated by clonogenic assays.
RESULTS: NIS function was acutely reduced by short stimulation with the PKC activator phorbol 12-myristate 13-acetate and increased by its inhibition with staurosporine or prolonged phorbol 12-myristate 13-acetate exposure. Surprisingly, epidermal growth factor (EGF) caused a strong dose-dependent augmentation of radioiodide transport, accompanied by extracellular signal-regulated kinase (ERK)-1/2 activation. Both effects were completely abrogated by specific MAP kinase kinase (MEK) inhibitors, which also reduced basal NIS function. Hence, radioiodide uptake levels could differ 24-fold, depending on ERK activity. Biotinylation-immunoblotting and confocal microscopy revealed that EGF increases plasma membrane-localized NIS without affecting total cellular levels. EGF stimulation was sufficient to enhance the killing effect of (131)I on the cancer cells.
CONCLUSION: Thus, PKC and ERK signaling play important roles in the regulation of NIS function, and control of these signaling pathways may help enhance the efficacy of radioiodide cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18997042     DOI: 10.2967/jnumed.108.055764

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  8 in total

Review 1.  The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics.

Authors:  Takahiko Kogai; Gregory A Brent
Journal:  Pharmacol Ther       Date:  2012-06-29       Impact factor: 12.310

Review 2.  Flavonoids, Thyroid Iodide Uptake and Thyroid Cancer-A Review.

Authors:  Carlos F L Gonçalves; Mariana L de Freitas; Andrea C F Ferreira
Journal:  Int J Mol Sci       Date:  2017-06-12       Impact factor: 5.923

3.  Positive radionuclide imaging of miRNA expression using RILES and the human sodium iodide symporter as reporter gene is feasible and supports a protective role of miRNA-23a in response to muscular atrophy.

Authors:  Viorel Simion; Julien Sobilo; Rudy Clemoncon; Sharuja Natkunarajah; Safia Ezzine; Florence Abdallah; Stephanie Lerondel; Chantal Pichon; Patrick Baril
Journal:  PLoS One       Date:  2017-05-11       Impact factor: 3.240

4.  Extracellular vesicles deliver sodium iodide symporter protein and promote cancer cell radioiodine therapy.

Authors:  Jin Hee Lee; Kyung-Ho Jung; Kim Mina; Kyung-Han Lee
Journal:  Sci Rep       Date:  2022-07-01       Impact factor: 4.996

Review 5.  Sodium iodide symporter (NIS) in extrathyroidal malignancies: focus on breast and urological cancer.

Authors:  Salvatore Micali; Stefania Bulotta; Cinzia Puppin; Angelo Territo; Michele Navarra; Giampaolo Bianchi; Giuseppe Damante; Sebastiano Filetti; Diego Russo
Journal:  BMC Cancer       Date:  2014-04-30       Impact factor: 4.430

6.  Enhancement of human sodium iodide symporter gene therapy for breast cancer by HDAC inhibitor mediated transcriptional modulation.

Authors:  Madhura G Kelkar; Kalimuthu Senthilkumar; Smita Jadhav; Sudeep Gupta; Beyong-Cheol Ahn; Abhijit De
Journal:  Sci Rep       Date:  2016-01-18       Impact factor: 4.379

7.  Targeting poor proteasomal function with radioiodine eliminates CT26 colon cancer stem cells resistant to bortezomib therapy.

Authors:  Jin Hee Lee; Kyung-Ho Jung; Jin Won Park; Seung Hwan Moon; Young Seok Cho; Kyung-Han Lee
Journal:  Sci Rep       Date:  2020-08-31       Impact factor: 4.379

8.  TNFα-mediated activation of NF-κB downregulates sodium-iodide symporter expression in thyroid cells.

Authors:  Márcia Faria; Rita Domingues; Francisca Paixão; Maria João Bugalho; Paulo Matos; Ana Luísa Silva
Journal:  PLoS One       Date:  2020-02-12       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.